Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin in osteoblasts

被引:78
|
作者
Takami, M
Takahashi, N
Udagawa, N
Miyaura, C
Suda, K
Woo, JT
Martin, TJ
Nagai, K
Suda, T
机构
[1] Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 1428555, Japan
[2] Tokyo Inst Technol, Dept Bioengn, Yokohama, Kanagawa 2268501, Japan
[3] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Biochem, Tokyo 1920392, Japan
[4] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia
关键词
D O I
10.1210/en.141.12.4711
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) produced by osteoblasts/stromal cells are involved as positive and negative regulators in osteoclast formation. Three independent signals have been proposed to induce RANKL expression in osteoblasts/stromal cells: vitamin D receptor-, cAMP-, and gp130-mediated signals. We previously reported that intracellular calcium-elevating compounds such as ionomycin, cyclopiazonic acid, and thapsigargin induced osteoclast formation in cocultures of mouse bone marrow cells and primary osteoblasts. Increases in calcium concentration in culture medium also induced osteoclast formation in cocultures. Treatment of primary osteoblasts with these compounds or with high calcium medium stimulated the expression of both RANKL and OPG messenger RNAs (mRNAs). 1,2-Bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid)-tetra(acetoxymethyl)ester, an intracellular calcium chelator, suppressed both ionamycin-induced osteoclast formation in cocultures and expression of RANKL and OPG mRNAs in primary osteoblasts. Phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C, also stimulated osteoclast formation in these cocultures and the expression of RANKL and OPG mRNAs in primary osteoblasts. Protein kinase C inhibitors such as calphostin and staurosporin suppressed ionomycin- and PMA-induced osteoclast formation in cocultures and expression of RANKL and OPG mRNAs in primary osteoblasts. Ionomycin stimulated RANKL mRNA expression in ST2 and MC3T3-G2/PA6 cells, but not in MC3T3-E1 or NIH-3T3 cells. These effects were closely correlated with osteoclast formation in response to ionomycin in cocultures with these stromal cell lines. OPG strongly inhibited osteoclast formation induced by calcium-elevating compounds and PMA in cocultures, suggesting that RANKL expression in osteoblasts is a rate-limiting step for osteoclast induction. Forskolin, an activator of cAMP signals, also stimulated osteoclast formation in cocultures. Forskolin enhanced RANKL mRNA expression but suppressed OPG mRNA expression in primary osteoblasts. These results suggest that the calcium/protein kinase C signal in osteoblasts/stromal cells is the fourth signal for inducing RANKL mRNA expression, which, in turn, stimulates osteoclast formation.
引用
收藏
页码:4711 / 4719
页数:9
相关论文
共 50 条
  • [31] Differential expression of periostin, sclerostin, receptor activator of nuclear factor-κB, and receptor activator of nuclear factor-κB ligand genes in severe chronic periodontitis
    Sankardas, Pooja A.
    Lavu, Vamsi
    Lakakula, Bhaskar V. K. S.
    Rao, Suresh R.
    JOURNAL OF INVESTIGATIVE AND CLINICAL DENTISTRY, 2019, 10 (01) : e12369
  • [32] Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-κB Ligand in Periodontitis
    Balli, Umut
    Aydogdu, Ahmet
    Dede, Figen Ongoz
    Turer, Cigdem Coskun
    Guven, Berrak
    JOURNAL OF PERIODONTOLOGY, 2015, 86 (12) : 1396 - 1404
  • [33] Receptor activator of nuclear factor-κB ligand activates nuclear factor-κB in osteoclast precursors
    Wei, S
    Teitelbaum, SL
    Wang, MWH
    Ross, FP
    ENDOCRINOLOGY, 2001, 142 (03) : 1290 - 1295
  • [34] Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues
    Liu, Wei
    Zhang, Xianlong
    MOLECULAR MEDICINE REPORTS, 2015, 11 (05) : 3212 - 3218
  • [35] Osteoprotegerin-receptor activator of nuclear factor-κB ligand ratio:: A new approach to osteoporosis treatment?
    Coetzee, M
    Kruger, MC
    SOUTHERN MEDICAL JOURNAL, 2004, 97 (05) : 506 - 511
  • [36] Osteoprotegerin/receptor activator of nuclear factor-κB ligand are involved in periodontitis-promoted vascular calcification
    Jiao, Mengyu
    Zhang, Pengmei
    Yu, Xinbo
    Sun, Pei
    Liu, Meiwei
    Qiao, Yanya
    Pan, Keqing
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (02)
  • [37] Soluble receptor activator of nuclear factor-κB ligand (sRANKL)/osteoprotegerin balance in polymyalgia rheumatica.
    Dolzani, P
    Silvestri, R
    Pulsatelli, L
    Facchini, A
    Boiardi, L
    Salvarani, C
    Meliconi, R
    Codivilla-Putti, I
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S435 - S435
  • [38] The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases
    Hofbauer, LC
    Heufelder, AE
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (07): : 2355 - 2363
  • [39] Expression profiles of receptor activator of nuclear factor κB ligand, receptor activator of nuclear factor κB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones
    Ikeda, T
    Utsuyama, M
    Hirokawa, K
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (08) : 1416 - 1425
  • [40] Effects of Enterococcus faecalis lipoteichoic acid on receptor activator of nuclear factor-κB ligand and osteoprotegerin expression in periodontal ligament fibroblasts
    Zhao, L.
    Chen, J.
    Cheng, L.
    Wang, X.
    Du, J.
    Wang, F.
    Peng, Z.
    INTERNATIONAL ENDODONTIC JOURNAL, 2014, 47 (02) : 163 - 172